Valuation
- Market cap
- 58,235,000
- Revenue TTM
- $66,800,000
- Net income TTM
- $8,570,000
- P/E (trailing)
- 9.27
- P/E (forward)
- —
- Profit margin
- 12.83%
- Debt to equity
- 0.00
Trading
- Volume
- 357,400
- Avg volume
- 573,884
- Day's range
- $0.95 – $1.04
- Shares out
- 58,235,000
- Stochastic %K
- 35%
- Beta
- 1.59
- Analysts
- Moderate Buy
- Price target
- $6.00
Company profile
Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying and developing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include Tebipenem HBr (tebipenem pivoxil hydrobromide), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for ad...
Show more
Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying and developing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include Tebipenem HBr (tebipenem pivoxil hydrobromide), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adult patients, which has completed second Phase 3 trial. It has license agreement with Meiji Seika Pharma Co., Ltd. to develop, manufacture, and commercialize tebipenem pivoxil and tebipenem HBr; and Everest Medicines to develop, manufacture, and commercialize SPR206 in Greater China, South Korea, and Southeast Asian countries. Spero Therapeutics, Inc. was incorporated in 2013 and is headquartered in Cambridge, Massachusetts.
- Industry
- Biotechnology
- Sector
- Healthcare
- Phone
- 857 242 1600
- Website
- https://sperotherapeutics.com
- Address
- 675 Massachusetts Avenue, 14th Floor, Cambridge, United States
Latest news
No headlines yet.
